Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology · 2026-11 · 20 (11) · 2876-2895
DOI: 10.1002/1878-0261.70266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 07.05.2026. Verfasst von Matthew O Ellis und 3 weiteren Autor:innen. Beteiligte Einrichtung: UK-DRI, Department of Clinical Neuroscience, University of Cambridge, Cambridge, England. Hauptthemen laut MEDLINE: DNA End-Joining Repair, Receptor, IGF Type 1, DNA-Activated Protein Kinase, Chromatin. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Medical Research Council, Prostate Cancer UK.
Abstract (Originalsprache)
The insulin‐like growth factor (IGF) axis regulates cancer cell proliferation, growth, invasion, and therapy resistance. Elevated expression of the type 1 IGF receptor (IGF‐1R) is linked to radioresistance and biochemical recurrence in prostate cancer, yet the molecular mechanisms underlying IGF‐1R–mediated DNA damage responses remain unclear. We investigated the role of IGF‐1R in DNA double‐strand break (DSB) repair by assessing chromatin recruitment of DNA repair proteins, repair pathway usage, and therapeutic sensitivity in cancer cell models with altered IGF‐1R status. Loss of IGF‐1R impaired DNA‐dependent protein kinase catalytic subunit (DNA‐PKcs) localisation to chromatin, resulting in defective non‐homologous end‐joining (NHEJ) and a compensatory reliance on alternative repair pathways, including microhomology‐mediated end‐joining (MMEJ). Modulating IGF‐1R expression restored radiosensitivity in poly (ADP‐ribose) polymerase (PARP) inhibitor–resistant breast cancer cells. IGF‐1R inhibition compromises canonical DSB repair and re‐sensitises resistant cancer cells to therapy, supporting its potential as a therapeutic strategy in homologous recombination–deficient tumours. Furthermore, IGF‐1R mutant cancers may benefit from targeted inhibition of the MMEJ pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UK-DRI, Department of Clinical Neuroscience, University of Cambridge, Cambridge, England.
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, England.
- Institute of Cancer Research, London, England.
ORCID-Profile: Matthew O Ellis, Wojciech Niedzwiedz
Förderung
- Cancer Research UK
- Medical Research Council
- Prostate Cancer UK
Zitieren
APA
Ellis, M. O., Mills, J. V., Niedzwiedz, W., & Macaulay, V. M. (2026). Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining. Molecular Oncology, 20(11), 2876-2895. https://doi.org/10.1002/1878-0261.70266
Vancouver
Ellis MO, Mills JV, Niedzwiedz W, Macaulay VM. Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining. Molecular Oncology. 2026;20(11):2876-2895. doi:10.1002/1878-0261.70266
BibTeX
@article{Ellis2026,
author = {Ellis, Matthew O and Mills, Jack V and Niedzwiedz, Wojciech and Macaulay, Valentine M},
title = {Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2876--2895},
doi = {10.1002/1878-0261.70266}
}
EUVIMED